Precision BioSciences (English Wikipedia)

Graff, Gregory D.; Sherkow, Jacob S. (2020-08-31). "Models of Technology Transfer for Genome-Editing Technologies". Annual Review of Genomics and Human Genetics. 21 (1): 509–534. doi:10.1146/annurev-genom-121119-100145. hdl:2142/110346. ISSN 1527-8204. PMID 32151165. S2CID 212652569.
Meng, Da; Ragi, Sara D.; Tsang, Stephen H. (2020). "Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa". Molecular Therapy. 28 (10): 2139–2149. doi:10.1016/j.ymthe.2020.08.012. PMC 7545001. PMID 32882181. Given that Cas9 genes themselves are approaching the size limit of AAV vectors, usage of long promoters to increase specificity and expression level is prohibited. ... ARCUS meganuclease is much smaller (~300 aa) and does not require gRNAs, making it easier to deliver via a single AAV vector.
Gorsuch, Cassandra L.; Nemec, Paige; Yu, Mei; Xu, Simin; Han, Dong; Smith, Jeff; Lape, Janel; Van Buuren, Nicholas; Ramirez, Ricardo; Muench, Robert C.; Holdorf, Meghan M.; Feierbach, Becket; Falls, Greg; Holt, Jason; Shoop, Wendy; Sevigny, Emma; Karriker, Forrest; Brown, Robert V.; Joshi, Amod; Goodwin, Tyler; Tam, Ying K.; Lin, Paulo J.C.; Semple, Sean C.; Leatherbury, Neil; Delaney Iv, William E.; Jantz, Derek; Rhoden Smith, Amy (2022). "Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo". Molecular Therapy. 30 (9): 2909–2922. doi:10.1016/j.ymthe.2022.05.013. PMC 9481990. PMID 35581938. S2CID 248849628.

fiercebiotech.com (Global: low place; English: 8,828^th place)

Taylor, Nick Paul (26 June 2018). "Precision BioSciences bags $110M to take off-the-shelf CAR-T into humans". Fierce Biotech. Retrieved 8 August 2022.
Idrus, Amirah Al (20 November 2020). "Lilly, Precision Biosciences team up on Duchenne gene therapy in $135M deal". Fierce Biotech. Retrieved 22 July 2022.
Bayer, Max (May 23, 2022). "Precision BioSciences makes case for 2 gene editing programs over CRISPR with preclinical data". Fierce Biotech. Retrieved 8 August 2022.
Weintraub, Arlene (29 September 2021). "In vivo gene editing grabs the spotlight after Intellia triumph, but challenges loom". Fierce Biotech. Retrieved 9 August 2022.
Bayer, Max (June 8, 2022). "Precision hails phase 1/2 data as proof it could deliver the first approved off-the-shelf CAR-T". Retrieved 8 August 2022.

fiercepharma.com (Global: low place; English: 8,921^st place)

Saxena, Varun (12 May 2015). "Gene editing player gets $25M in Series A round". Fierce Pharma. Retrieved 8 August 2022.

genengnews.com (Global: low place; English: 6,625^th place)

Shaffer, Catherine (5 January 2022). "Novel Gene Editing Systems Come Into Their Own". Genetic Engineering and Biotechnology News. Retrieved 22 July 2022.
Sarkar, Anjali A. (23 February 2021). "Preclinical Study Shows Safety, Efficacy, and Durability of Lowering LDL-Cholesterol Levels Long-Term in Non-Human Primates". GEN - Genetic Engineering and Biotechnology News. Retrieved 9 August 2022.

handle.net (Global: 102^nd place; English: 76^th place)

hdl.handle.net

Graff, Gregory D.; Sherkow, Jacob S. (2020-08-31). "Models of Technology Transfer for Genome-Editing Technologies". Annual Review of Genomics and Human Genetics. 21 (1): 509–534. doi:10.1146/annurev-genom-121119-100145. hdl:2142/110346. ISSN 1527-8204. PMID 32151165. S2CID 212652569.

healio.com (Global: low place; English: low place)

Amorosi, Drew (10 August 2021). "One-step gene-editing technique opens door to safe, effective off-the-shelf CAR T cells". Healio. Retrieved 22 July 2022.

informa.com (Global: low place; English: low place)

pink.pharmaintelligence.informa.com

McConaghie, Andrew (30 March 2022). "'We'll Be First With Off-The-Shelf CAR-T,' Vows Precision Biosciences – And Hopes To Win Over Gene-Editing Skeptics". Informa Pharma Intelligence. Retrieved 9 August 2022.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Graff, Gregory D.; Sherkow, Jacob S. (2020-08-31). "Models of Technology Transfer for Genome-Editing Technologies". Annual Review of Genomics and Human Genetics. 21 (1): 509–534. doi:10.1146/annurev-genom-121119-100145. hdl:2142/110346. ISSN 1527-8204. PMID 32151165. S2CID 212652569.
Meng, Da; Ragi, Sara D.; Tsang, Stephen H. (2020). "Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa". Molecular Therapy. 28 (10): 2139–2149. doi:10.1016/j.ymthe.2020.08.012. PMC 7545001. PMID 32882181. Given that Cas9 genes themselves are approaching the size limit of AAV vectors, usage of long promoters to increase specificity and expression level is prohibited. ... ARCUS meganuclease is much smaller (~300 aa) and does not require gRNAs, making it easier to deliver via a single AAV vector.
Gorsuch, Cassandra L.; Nemec, Paige; Yu, Mei; Xu, Simin; Han, Dong; Smith, Jeff; Lape, Janel; Van Buuren, Nicholas; Ramirez, Ricardo; Muench, Robert C.; Holdorf, Meghan M.; Feierbach, Becket; Falls, Greg; Holt, Jason; Shoop, Wendy; Sevigny, Emma; Karriker, Forrest; Brown, Robert V.; Joshi, Amod; Goodwin, Tyler; Tam, Ying K.; Lin, Paulo J.C.; Semple, Sean C.; Leatherbury, Neil; Delaney Iv, William E.; Jantz, Derek; Rhoden Smith, Amy (2022). "Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo". Molecular Therapy. 30 (9): 2909–2922. doi:10.1016/j.ymthe.2022.05.013. PMC 9481990. PMID 35581938. S2CID 248849628.

ncbi.nlm.nih.gov

Meng, Da; Ragi, Sara D.; Tsang, Stephen H. (2020). "Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa". Molecular Therapy. 28 (10): 2139–2149. doi:10.1016/j.ymthe.2020.08.012. PMC 7545001. PMID 32882181. Given that Cas9 genes themselves are approaching the size limit of AAV vectors, usage of long promoters to increase specificity and expression level is prohibited. ... ARCUS meganuclease is much smaller (~300 aa) and does not require gRNAs, making it easier to deliver via a single AAV vector.
Gorsuch, Cassandra L.; Nemec, Paige; Yu, Mei; Xu, Simin; Han, Dong; Smith, Jeff; Lape, Janel; Van Buuren, Nicholas; Ramirez, Ricardo; Muench, Robert C.; Holdorf, Meghan M.; Feierbach, Becket; Falls, Greg; Holt, Jason; Shoop, Wendy; Sevigny, Emma; Karriker, Forrest; Brown, Robert V.; Joshi, Amod; Goodwin, Tyler; Tam, Ying K.; Lin, Paulo J.C.; Semple, Sean C.; Leatherbury, Neil; Delaney Iv, William E.; Jantz, Derek; Rhoden Smith, Amy (2022). "Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo". Molecular Therapy. 30 (9): 2909–2922. doi:10.1016/j.ymthe.2022.05.013. PMC 9481990. PMID 35581938. S2CID 248849628.

oncozine.com (Global: low place; English: low place)

"CAR T-cell Therapies for the Treatment of Patients with Acute Lymphoblastic Leukemia". Onco'Zine. 13 October 2020. Retrieved 9 August 2022.

pharmtech.com (Global: low place; English: low place)

"Precision BioSciences Releases Data on CAR T Therapy Candidates". PharmTech. 13 June 2022. Retrieved 2022-08-08.

precisionbiosciences.com (Global: low place; English: low place)

investor.precisionbiosciences.com

"Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update". Precision BioSciences (Press release). 15 March 2022. Retrieved 9 August 2022.
"Form 10-Q: Quarterly report which provides a continuing view of a company's financial position". Precision BioSciences. 30 June 2022. Retrieved 9 August 2022.

scienceboard.net (Global: low place; English: low place)

"Precision and Iecure ink collaboration deal". The Science Advisory Board. 9 September 2021. Retrieved 24 August 2022.

sec.gov (Global: 572^nd place; English: 436^th place)

"Precision Biosciences S-1 Filing". U.S. Securities and Exchange Commission. 1 March 2019. Retrieved 2022-08-08.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Graff, Gregory D.; Sherkow, Jacob S. (2020-08-31). "Models of Technology Transfer for Genome-Editing Technologies". Annual Review of Genomics and Human Genetics. 21 (1): 509–534. doi:10.1146/annurev-genom-121119-100145. hdl:2142/110346. ISSN 1527-8204. PMID 32151165. S2CID 212652569.
Gorsuch, Cassandra L.; Nemec, Paige; Yu, Mei; Xu, Simin; Han, Dong; Smith, Jeff; Lape, Janel; Van Buuren, Nicholas; Ramirez, Ricardo; Muench, Robert C.; Holdorf, Meghan M.; Feierbach, Becket; Falls, Greg; Holt, Jason; Shoop, Wendy; Sevigny, Emma; Karriker, Forrest; Brown, Robert V.; Joshi, Amod; Goodwin, Tyler; Tam, Ying K.; Lin, Paulo J.C.; Semple, Sean C.; Leatherbury, Neil; Delaney Iv, William E.; Jantz, Derek; Rhoden Smith, Amy (2022). "Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo". Molecular Therapy. 30 (9): 2909–2922. doi:10.1016/j.ymthe.2022.05.013. PMC 9481990. PMID 35581938. S2CID 248849628.

thepharmaletter.com (Global: low place; English: low place)

"Precision BioSciences and Tiziana Life Sciences partner on foralumab". The Pharma Letter. 2 September 2021. Retrieved 16 August 2022.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Graff, Gregory D.; Sherkow, Jacob S. (2020-08-31). "Models of Technology Transfer for Genome-Editing Technologies". Annual Review of Genomics and Human Genetics. 21 (1): 509–534. doi:10.1146/annurev-genom-121119-100145. hdl:2142/110346. ISSN 1527-8204. PMID 32151165. S2CID 212652569.

wraltechwire.com (Global: low place; English: low place)

Haskins, Bryant (18 September 2021). "Precision Biosciences inks gene editing deal with iECURE". WRAL TechWire. Retrieved 24 August 2022.

Precision BioSciences (English Wikipedia)

annualreviews.org (Global: 3,867th place; English: 3,957th place)

biospace.com (Global: low place; English: 7,595th place)

bizjournals.com (Global: 407th place; English: 241st place)

clinicaltrials.gov (Global: 5,225th place; English: 4,062nd place)

doi.org (Global: 2nd place; English: 2nd place)

fiercebiotech.com (Global: low place; English: 8,828th place)

fiercepharma.com (Global: low place; English: 8,921st place)

genengnews.com (Global: low place; English: 6,625th place)

handle.net (Global: 102nd place; English: 76th place)

hdl.handle.net

healio.com (Global: low place; English: low place)

informa.com (Global: low place; English: low place)

pink.pharmaintelligence.informa.com

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

oncozine.com (Global: low place; English: low place)

pharmtech.com (Global: low place; English: low place)

precisionbiosciences.com (Global: low place; English: low place)

investor.precisionbiosciences.com

scienceboard.net (Global: low place; English: low place)

sec.gov (Global: 572nd place; English: 436th place)

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

thepharmaletter.com (Global: low place; English: low place)

worldcat.org (Global: 5th place; English: 5th place)

search.worldcat.org

wraltechwire.com (Global: low place; English: low place)

annualreviews.org (Global: 3,867^th place; English: 3,957^th place)

biospace.com (Global: low place; English: 7,595^th place)

bizjournals.com (Global: 407^th place; English: 241^st place)

clinicaltrials.gov (Global: 5,225^th place; English: 4,062^nd place)

doi.org (Global: 2^nd place; English: 2^nd place)

fiercebiotech.com (Global: low place; English: 8,828^th place)

fiercepharma.com (Global: low place; English: 8,921^st place)

genengnews.com (Global: low place; English: 6,625^th place)

handle.net (Global: 102^nd place; English: 76^th place)

nih.gov (Global: 4^th place; English: 4^th place)

sec.gov (Global: 572^nd place; English: 436^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

worldcat.org (Global: 5^th place; English: 5^th place)